Zacks Investment Research upgraded shares of Dermira (NASDAQ:DERM) from a sell rating to a hold rating in a report released on Friday, March 16th.
According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “
A number of other research analysts also recently weighed in on the company. BidaskClub raised Dermira from a sell rating to a hold rating in a research note on Thursday, March 15th. Needham & Company LLC dropped their price target on Dermira from $43.00 to $19.00 and set a buy rating on the stock in a research note on Tuesday, March 6th. Guggenheim downgraded Dermira from a buy rating to a neutral rating in a research note on Tuesday, March 6th. Cantor Fitzgerald set a $20.00 price target on Dermira and gave the stock a buy rating in a research note on Monday, March 5th. Finally, Mizuho downgraded Dermira from a buy rating to a neutral rating in a research note on Monday, March 5th. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock has an average rating of Buy and a consensus price target of $32.71.
DERM stock traded down $0.48 during trading on Friday, reaching $7.12. 2,437,004 shares of the stock were exchanged, compared to its average volume of 1,350,944. Dermira has a twelve month low of $6.98 and a twelve month high of $35.76. The company has a debt-to-equity ratio of 1.87, a quick ratio of 5.28 and a current ratio of 5.28. The company has a market cap of $297.77, a P/E ratio of -1.62 and a beta of 1.52.
Dermira (NASDAQ:DERM) last posted its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.25) by ($0.09). Dermira had a negative return on equity of 62.07% and a negative net margin of 6,678.29%. The firm had revenue of $1.34 million for the quarter, compared to analyst estimates of $1.10 million. equities analysts predict that Dermira will post -4.81 earnings per share for the current year.
In other Dermira news, insider Eugene A. Bauer sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $28.55, for a total transaction of $85,650.00. Following the completion of the sale, the insider now directly owns 5,802 shares of the company’s stock, valued at approximately $165,647.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 4,700 shares of company stock valued at $131,142 over the last three months. Corporate insiders own 13.30% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the business. Quantbot Technologies LP increased its holdings in Dermira by 75.4% during the 3rd quarter. Quantbot Technologies LP now owns 5,371 shares of the biopharmaceutical company’s stock worth $145,000 after purchasing an additional 2,309 shares in the last quarter. Aperio Group LLC bought a new stake in Dermira during the 4th quarter worth approximately $213,000. Two Sigma Advisers LP bought a new stake in Dermira during the 4th quarter worth approximately $222,000. SG Americas Securities LLC increased its holdings in Dermira by 47.7% during the 3rd quarter. SG Americas Securities LLC now owns 8,130 shares of the biopharmaceutical company’s stock worth $220,000 after purchasing an additional 2,627 shares in the last quarter. Finally, Teacher Retirement System of Texas bought a new stake in Dermira during the 4th quarter worth approximately $283,000. 94.93% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This article was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.dispatchtribunal.com/2018/04/09/dermira-derm-upgraded-to-hold-by-zacks-investment-research.html.
Dermira, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis.
Get a free copy of the Zacks research report on Dermira (DERM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.